PapersPMID:27270872
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.
- 01 · findings
- 6
- 02 · compound
- 1
- 03 · endpoints
- 6
- 04 · null
- 0
curcumin- Dose studied, every finding
- amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
- Population, every finding
- adults with ultrasound-diagnosed nonalcoholic fatty liver disease
What moved
6 findingsHow to read these marks →curcumin — decreases glycated haemoglobin (HbA1c)
very limitedFindingreplicated ×4
“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. - Study
- RCT
- Duration
- 8 weeks
curcumin — decreases aspartate aminotransferase
very limitedFindingreplicated ×6
“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. - Study
- RCT
- Duration
- 8 weeks
curcumin — decreases LDL cholesterol
very limitedFindingreplicated ×1
“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. - Study
- RCT
- Duration
- 8 weeks
curcumin — decreases alanine aminotransferase
very limitedFindingreplicated ×3
“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. - Study
- RCT
- Duration
- 8 weeks
curcumin — decreases triglycerides
very limitedFindingreplicated ×4
“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. - Study
- RCT
- Duration
- 8 weeks
curcumin — decreases total cholesterol (TC)
very limitedFindingreplicated ×4
“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. - Study
- RCT
- Duration
- 8 weeks
Study record
- Read under
- curcumin
- Design
- randomised controlled trial
- Species
- human
- Population
- adults with ultrasonographic evidence of nonalcoholic fatty liver disease
- Participants
- not recorded
- Comparator
- placebo
- Duration
- 56 days
- Endpoints measured
- 2
- Record
- extracted
- Readings recorded
- 2